{"id":32218,"date":"2026-03-04T01:20:10","date_gmt":"2026-03-04T01:20:10","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/32218\/"},"modified":"2026-03-04T01:20:10","modified_gmt":"2026-03-04T01:20:10","slug":"novo-nordisk-deepens-oral-glp-1-bet-with-vivtex-deal-and-ireland-spend","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/32218\/","title":{"rendered":"Novo Nordisk Deepens Oral GLP 1 Bet With Vivtex Deal And Ireland Spend"},"content":{"rendered":"\n

Never miss an important update on your stock portfolio<\/a> and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.<\/p>\n

Novo Nordisk has entered a partnership with Vivtex to develop next generation oral biologic medicines for obesity and diabetes.<\/p>\n

The company has approved a \u20ac432 million investment to expand its oral tablet manufacturing facility in Ireland.<\/p>\n

The expansion is aimed at increasing capacity for oral GLP-1 treatments, including the newly FDA approved oral Wegovy.<\/p>\n

Novo Nordisk, traded as CPSE:NOVO B, is leaning further into oral treatments at a time when its share price stands at DKK231.5. The stock has seen sizeable volatility, with a 37.4% decline over the past 30 days and a 61.4% decline over the past year, while still showing a 14.1% gain over five years. These moves provide important context for investors assessing how new projects in oral obesity and diabetes care fit into the broader story.<\/p>\n

The Vivtex partnership and Irish capacity build out focus on oral GLP-1 medicines that have historically relied on injections. For you as an investor, the key questions are how effectively Novo Nordisk can turn these initiatives into viable products at scale and how that might influence its role in obesity and diabetes treatment over time.<\/p>\n

Stay updated on the most important news stories for Novo Nordisk<\/a> by adding it to your watchlist<\/a> or portfolio<\/a>. Alternatively, explore our Community<\/a> to discover new perspectives on Novo Nordisk.<\/p>\n

\"CPSE:NOVO<\/a> CPSE:NOVO B Earnings & Revenue Growth as at Mar 2026 <\/p>\n

\ud83d\udcf0 Beyond the headline: 5 risks and 4 things going right for Novo Nordisk that every investor should see.<\/a><\/p>\n

The Vivtex partnership and the \u20ac432 million Athlone investment point in the same direction: Novo Nordisk is trying to secure a meaningful position in oral GLP-1 treatments rather than rely only on injectables. Vivtex brings drug delivery technology designed to improve how large biologic molecules are absorbed in the gut, while Novo puts its weight behind large scale production capacity in Ireland for oral Wegovy and future GLP-1 tablets. For you, the link between the two is important. If oral formulations continue to gain traction in obesity and diabetes care, the combination of proprietary delivery know how and dedicated tabletting capacity could matter for how competitive Novo Nordisk is versus Eli Lilly and other large pharma peers that are also working on oral GLP-1s.<\/p>\n

The Athlone expansion supports the existing narrative that future returns may rely increasingly on oral obesity treatments by adding capacity for current and pipeline GLP-1 tablets.<\/p>\n

The scale of investment and partnership related spending could pressure free cash flow in the near term, which connects to concerns in the narrative about high capital expenditure and earnings quality if demand is less robust than expected.<\/p>\n

The Vivtex collaboration introduces a new oral biologics platform that is not fully reflected in the earlier narrative focus on Wegovy, Ozempic and existing injectable and oral pipelines.<\/p>\n

Story continues <\/p>\n

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Novo Nordisk<\/a> to help decide what it is worth to you.<\/p>\n

\u26a0\ufe0f Large manufacturing projects and external technology partnerships add execution risk, especially if regulatory timelines or physician uptake for oral GLP-1s differ from expectations.<\/p>\n

\u26a0\ufe0f Analysts have flagged five key risks for Novo Nordisk, including share price volatility and concerns around earnings quality, which can influence how the market reacts to heavy investment in new formats like oral biologics.<\/p>\n

\ud83c\udf81 The Ireland expansion is expected to increase supply for oral GLP-1 products outside the US, which could help address past capacity constraints if demand for oral Wegovy and similar drugs remains strong.<\/p>\n

\ud83c\udf81 The Vivtex agreement gives Novo Nordisk access to a gastrointestinal screening and AI supported formulation platform that is specifically designed for oral biologic medicines, potentially broadening its future product range beyond current GLP-1 offerings.<\/p>\n

From here, you may want to watch three things. First, how quickly physicians and patients adopt oral Wegovy versus injectable options as more data and real world experience build up. Second, concrete milestones from the Vivtex collaboration, such as selection of lead oral biologic candidates or movement into clinical trials. Third, progress at the Athlone site, including whether the project stays on time and on budget as construction runs through 2028. These will help you judge whether Novo Nordisk is turning its spend on oral technologies and capacity into a sustainable position in obesity and diabetes care.<\/p>\n

To ensure you are always in the loop on how the latest news impacts the investment narrative for Novo Nordisk, head to the community page for Novo Nordisk to never miss an update on the top community narratives.<\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.<\/p>\n

Companies discussed in this article include NOVO-B.CO<\/a>.<\/p>\n

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors…\n","protected":false},"author":2,"featured_media":759,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[16357,6736,3041,272,18580],"class_list":{"0":"post-32218","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-biologic-medicines","9":"tag-diabetes-care","10":"tag-ireland","11":"tag-novo-nordisk","12":"tag-oral-treatments"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116168282849418463","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/32218","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=32218"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/32218\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/759"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=32218"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=32218"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=32218"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}